Vandetanib in non-cisplatin fit patients with urothelial cancers - A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin.

Trial Profile

Vandetanib in non-cisplatin fit patients with urothelial cancers - A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Vandetanib (Primary) ; Carboplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms TOUCAN
  • Most Recent Events

    • 28 Jan 2016 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 09 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 07 Jan 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top